biostudies-literatureCastle JRNIDDK NIH HHS892-897https://www.ebi.ac.uk/biostudies/studies/S-EPMC9700374biostudies-literatureUnknown24(12)Introduction: DailyDose is a decision support system designed to provide real-time dosing advice and weekly insulin dose adjustments for adults living with type 1 diabetes using multiple daily insulin injections. Materials and Methods: Twenty-five adults were enrolled in this single-arm study. All participants used Dexcom G6 for continuous glucose monitoring, InPen for short-acting insulin doses, and Clipsulin to track long-acting insulin doses. Participants used DailyDose on an iPhone for 8 weeks. The primary endpoint was % time in range (TIR) comparing the 2-week baseline to the final 2-week period of DailyDose use. Results: There were no significant differences between TIR or other glycemic metrics between the baseline period compared to final 2-week period of DailyDose use. TIR significantly improved by 6.3% when more than half of recommendations were accepted and followed compared with 50% or fewer recommendations (95% CI 2.5%-10.1%, P = 0.001). Conclusions: Use of DailyDose did not improve glycemic outcomes compared to the baseline period. In a post hoc analysis, accepting and following recommendations from DailyDose was associated with improved TIR. Clinical Trial Registration Number: NCT04428645.Diabetes technology & therapeuticsAssessment of a Decision Support System for Adults with Type 1 Diabetes on Multiple Daily Insulin Injections.PMC9700374R01 DK120367F30 DK128914Wilson LMEspinoza AZJacobs PGKushner TCastle JROganessian SMWinters-Stone KYoung GMTyler NSHilts WWPinsonault JBranigan DLRamsey KCafazzo JADodier RHEom JHMosquera-Lopez CMGabo VBYoussef JEfalseAssessment of a Decision Support System for Adults with Type 1 Diabetes on Multiple Daily Insulin Injections.Introduction: DailyDose is a decision support system designed to provide real-time dosing advice and weekly insulin dose adjustments for adults living with type 1 diabetes using multiple daily insulin injections. Materials and Methods: Twenty-five adults were enrolled in this single-arm study. All participants used Dexcom G6 for continuous glucose monitoring, InPen for short-acting insulin doses, and Clipsulin to track long-acting insulin doses. Participants used DailyDose on an iPhone for 8 weeks. The primary endpoint was % time in range (TIR) comparing the 2-week baseline to the final 2-week period of DailyDose use. Results: There were no significant differences between TIR or other glycemic metrics between the baseline period compared to final 2-week period of DailyDose use. TIR significantly improved by 6.3% when more than half of recommendations were accepted and followed compared with 50% or fewer recommendations (95% CI 2.5%-10.1%, P = 0.001). Conclusions: Use of DailyDose did not improve glycemic outcomes compared to the baseline period. In a post hoc analysis, accepting and following recommendations from DailyDose was associated with improved TIR. Clinical Trial Registration Number: NCT04428645.2022-01-01T00:00:00Z2022 Dec2026-05-29T00:47:01.541Z2025-04-05T19:03:23.512ZS-EPMC97003743592083910.1089/dia.2022.0252